Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
48.11
+0.49 (+1.03%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
62
63
Next >
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
April 11, 2024
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments.
Via
InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
April 10, 2024
These reliable dividend payers offer yields of 3.3% and better at recent prices.
Via
The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
April 09, 2024
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
Via
The Motley Fool
Is Bristol Myers Squibb Stock a Buy?
March 28, 2024
The company is going through a rough patch.
Via
The Motley Fool
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
April 08, 2024
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA...
Via
Benzinga
Exposures
Product Safety
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
April 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
April 08, 2024
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts...
Via
Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
April 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
April 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
April 05, 2024
The most undervalued biotech stocks to buy in April are intriguing value options with mature biotech plays that boast impressive pipelines.
Via
InvestorPlace
FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
April 05, 2024
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard...
Via
Benzinga
Exposures
Product Safety
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
April 05, 2024
From
Bristol Myers Squibb
Via
Business Wire
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
April 03, 2024
These stocks could rocket higher, but they also present significant risks.
Via
The Motley Fool
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
April 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts
April 02, 2024
With interest rates poised to fall, acquisitions will become more numerous. Here are three potential takeover targets.
Via
InvestorPlace
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
April 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains
April 01, 2024
Uncover strategic moves by three pharma giants poised to capture trends and fulfill emerging healthcare needs.
Via
InvestorPlace
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
April 01, 2024
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati...
Via
Benzinga
The 3 Best Biotech Stocks to Buy in Q2 2024
March 29, 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2.
Via
InvestorPlace
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
March 28, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
March 28, 2024
From
Bristol Myers Squibb
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
March 28, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
March 27, 2024
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
Via
InvestorPlace
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
March 27, 2024
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April....
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
March 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.